×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Insulin Syringes Market Trends

ID: MRFR/Pharma/10549-HCR
128 Pages
Rahul Gotadki
February 2026

Insulin Syringes Market Research Report Information By Syringe Size (3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml), Others), By Disease (Type 1 Diabetes And Type 2 Diabetes), By End-use (Hospitals & Clinics, Homecare Settings, Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Insulin Syringes Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Insulin Syringes Market

The market for pharmaceutical insulin syringes is experiencing significant trends that show the changeable nature of diabetes management and its continued pursuit of more advanced, patient-friendly insulin delivery devices. One such trend is a rise in demand for safety-engineered insulin syringes. With patients’ welfare being a major concern, manufacturers include things like retractable needles, protective shields and other mechanisms of risk minimization against needle stick injuries as well as overall user safety enhancement. This trend also fits into the industry’s approach to improve user experience and minimize accidental needle pricks possibilities.

Technological advancements are pivotal in shaping the trends in Pharmaceutical Insulin Syringes Market. The development of ultra-fine and ultra-short needles has been informed by the integration of inventive materials, manufacturing techniques as well as design modifications. These transformations not just increase patients’ comfort when injecting themselves but also facilitate better absorption of insulin which could possibly reduce pain associated with subcutaneous injections. Therefore, technological innovation is focused on practical and physiological aspects related to insulin administration.

Additionally, there is an upsurge in pen-shaped insulin syringe adoption on the market today. Such simple-to-use products allow discreetness during injection periods hence offering flexibility to patients while using them. Pen-shaped syringes are popular because they can be carried around easily, have pre-filled cartridge options as well as dosage accuracy which enhances medication adherence leading to improved blood sugar control among diabetic patients. The focus here demonstrates ongoing endeavors directed towards enhancing patient experience and fostering self-management in diabetes care.

Yet another significant trend is sustainability aspects given priority in designing and making of insulin syringes. As a response to environmental effects linked with single-use medical equipment; manufacturers are considering eco-friendly materials for instance recyclable components; reduced packaging waste among others for production of sustainable insulin syringes respectively. In this regard, it harmonizes with broader movements toward sustainable healthcare practices hence reflecting industry commitment towards minimizing ecological footprints.

The Pharmaceutical Insulin Syringes Market is also influenced by the growing integration of digital technology in insulin delivery devices. Smart insulin pens and connected syringe systems are gaining traction, allowing patients to track and monitor their insulin injections through smartphone apps or other digital platforms. These digital solutions provide valuable data for both patients and healthcare providers, enabling better diabetes management, adherence tracking, and personalized treatment plans. The trend towards digital integration reflects the increasing role of technology in optimizing diabetes care and treatment outcomes.

Furthermore, market trends are shaped by regulatory initiatives and standards aimed at ensuring the safety, quality, and performance of insulin syringes. Manufacturers have to comply with regulations considering product design as well as labeling meeting up with a required overall quality control. In addition to that meeting regulatory standards cements the industry’s dedication towards providing highest safety and efficacy standards in relation to insulin syringes.

On the other hand, it highlights a shift from traditional approaches where one size fits all concepts were used when it came to treatment of diabetic individuals using insulin thus missing out on an approach that could address each patient’s individual needs. For example, manufacturers are currently looking into developing insulin syringes which cater for different patient groups such as age-specific designs; needle gauge options for instance having individuals with different levels of dexterity in mind among other features. This shows that there is realization within the sector that diverse patients have separate requirements hence requiring unique solutions for effective diabetes care.

Also, there is a response from the market to the increase in prevalence of diabetes worldwide and the resulting expansion in insulin delivery devices’ demand. The increased number of diabetic people across the globe has necessitated the use of affordable and user-friendly insulin syringes. This shows that there is a commitment on part of industry players to fight diabetes and ensure that insulin delivery options are easily accessible to all.

Author
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Insulin Syringes Market by 2035?

<p>The Insulin Syringes Market is projected to reach a valuation of 2.901 USD Billion by 2035.</p>

What was the market valuation of the Insulin Syringes Market in 2024?

<p>In 2024, the Insulin Syringes Market was valued at 1.844 USD Billion.</p>

What is the expected CAGR for the Insulin Syringes Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Insulin Syringes Market during the forecast period 2025 - 2035 is 4.2%.</p>

Which companies are considered key players in the Insulin Syringes Market?

<p>Key players in the Insulin Syringes Market include Becton Dickinson, Novo Nordisk, Sanofi, Eli Lilly, Terumo Corporation, Medtronic, Roche, Ypsomed, and Owen Mumford.</p>

What are the projected revenues for Type 1 and Type 2 Diabetes segments by 2035?

<p>By 2035, the projected revenues for Type 1 Diabetes and Type 2 Diabetes segments are expected to be 1.45 USD Billion and 1.451 USD Billion, respectively.</p>

How do the revenues of 3/10 CC Syringes compare to 1CC Syringes in 2024?

<p>In 2024, the revenue for 3/10 CC Syringes was 0.553 USD Billion, while 1CC Syringes also generated 0.553 USD Billion.</p>

What is the expected revenue for insulin syringes used in homecare settings by 2035?

The expected revenue for insulin syringes used in homecare settings by 2035 is projected to be 1.299 USD Billion.

What segment generated the highest revenue in the Insulin Syringes Market in 2024?

In 2024, the segment for Type 1 Diabetes generated the highest revenue at 0.922 USD Billion.

What is the revenue projection for the 'Others' category in the Syringe Size segment by 2035?

The revenue projection for the 'Others' category in the Syringe Size segment by 2035 is expected to be 0.677 USD Billion.

How does the revenue for hospitals and clinics compare to homecare settings in 2024?

In 2024, the revenue for hospitals and clinics was 0.738 USD Billion, while homecare settings generated a similar revenue of 0.738 USD Billion.

Market Summary

As per Market Research Future analysis, the Insulin Syringes Market Size was estimated at 1.844 USD Billion in 2024. The Insulin Syringes industry is projected to grow from 1.922 USD Billion in 2025 to 2.901 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.2% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Insulin Syringes Market is poised for growth driven by technological advancements and increasing diabetes awareness.

  • North America remains the largest market for insulin syringes, reflecting a robust healthcare infrastructure. The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising diabetes prevalence and healthcare investments. 1CC syringes dominate the market, while 3/10 CC syringes are experiencing rapid growth due to changing patient preferences. Key market drivers include the increasing prevalence of diabetes and technological innovations in syringe design.

Market Size & Forecast

2024 Market Size 1.844 (USD Billion)
2035 Market Size 2.901 (USD Billion)
CAGR (2025 - 2035) 4.2%
Largest Regional Market Share in 2024 North America

Major Players

Becton Dickinson (US), Novo Nordisk (DK), Sanofi (FR), Eli Lilly (US), <a href="https://www.terumo.com/newsrelease/detail/20231114/6011">Terumo Corporation </a>(JP), Medtronic (US), Roche (CH), Ypsomed (CH), Owen Mumford (GB)

Market Trends

The Insulin Syringes Market is currently experiencing notable transformations driven by various factors. The increasing prevalence of diabetes globally has led to a heightened demand for insulin delivery devices, particularly syringes. As healthcare systems evolve, there is a growing emphasis on patient-centric solutions, which has prompted manufacturers to innovate and enhance the usability of their products. Furthermore, advancements in technology are facilitating the development of more precise and user-friendly syringes, which may improve patient adherence to treatment regimens. This trend appears to be fostering a competitive landscape where companies strive to differentiate their offerings through design and functionality. In addition to technological advancements, regulatory frameworks are also shaping the Insulin Syringes Market. Governments and health organizations are implementing stricter guidelines to ensure safety and efficacy in medical devices. This regulatory scrutiny could lead to increased quality standards, thereby influencing production processes and market entry strategies. Moreover, the rising awareness of diabetes management among patients is likely to drive demand for insulin syringes, as individuals seek reliable and effective means of self-administration. Overall, the Insulin Syringes Market seems poised for growth, with various dynamics at play that could redefine its future landscape.

Technological Advancements

The Insulin Syringes Market is witnessing a surge in innovation, particularly in the development of smart syringes. These devices often incorporate features such as dose tracking and connectivity to mobile applications, which may enhance user experience and adherence to treatment protocols. As technology continues to evolve, the integration of digital health solutions into insulin delivery systems appears to be a key trend.

Regulatory Changes

Regulatory bodies are increasingly focusing on the safety and efficacy of medical devices, including insulin syringes. Stricter guidelines and quality standards are being established, which could impact manufacturing processes and market dynamics. This trend suggests that companies must adapt to comply with new regulations, potentially leading to improved product quality and patient safety.

Rising Diabetes Awareness

There is a growing awareness regarding diabetes management among patients and healthcare providers. Educational initiatives and outreach programs are likely contributing to this trend, encouraging individuals to seek effective solutions for insulin administration. As awareness increases, the demand for insulin syringes may rise, reflecting a shift towards proactive health management.

Insulin Syringes Market Market Drivers

Rising Geriatric Population

The increasing geriatric population is a significant factor influencing the Insulin Syringes Market. As individuals age, the risk of developing chronic conditions, including diabetes, escalates. The World Health Organization estimates that the number of people aged 60 years and older will reach 2 billion by 2050. This demographic shift is likely to result in a higher prevalence of diabetes among older adults, thereby driving the demand for insulin syringes. Moreover, older patients often require assistance with insulin administration, which may lead to a greater reliance on healthcare services and products. Consequently, the Insulin Syringes Market is expected to expand as healthcare systems adapt to meet the needs of this growing population segment.

Increasing Prevalence of Diabetes

The rising incidence of diabetes worldwide is a primary driver for the Insulin Syringes Market. According to recent statistics, the number of individuals diagnosed with diabetes has reached approximately 537 million, with projections indicating a potential increase to 643 million by 2030. This alarming trend necessitates the need for effective diabetes management solutions, including insulin syringes. As more patients require insulin therapy, the demand for insulin syringes is expected to grow significantly. Furthermore, the increasing prevalence of obesity, which is closely linked to type 2 diabetes, further exacerbates this situation. Consequently, healthcare providers are likely to emphasize the importance of insulin delivery systems, thereby propelling the Insulin Syringes Market forward.

Government Initiatives and Support

Government initiatives aimed at improving diabetes care and management are playing a crucial role in shaping the Insulin Syringes Market. Many countries are implementing policies to enhance access to diabetes treatment, including subsidizing the cost of insulin syringes for patients. These initiatives not only alleviate the financial burden on patients but also encourage adherence to prescribed treatment regimens. Furthermore, public health campaigns aimed at raising awareness about diabetes prevention and management are likely to increase the number of individuals seeking insulin therapy. As governments continue to prioritize diabetes care, the Insulin Syringes Market is poised for growth, driven by increased accessibility and support for patients.

Technological Innovations in Syringe Design

Technological advancements in the design and functionality of insulin syringes are transforming the Insulin Syringes Market. Innovations such as safety-engineered syringes, which reduce the risk of needlestick injuries, are gaining traction among healthcare professionals. Additionally, the introduction of pre-filled syringes and smart syringes equipped with digital tracking capabilities enhances patient compliance and monitoring. These advancements not only improve the user experience but also contribute to better health outcomes for patients. The market for insulin delivery devices is projected to grow at a compound annual growth rate (CAGR) of around 8.5% from 2023 to 2030, indicating a robust demand for innovative insulin syringes. As technology continues to evolve, the Insulin Syringes Market is likely to witness further enhancements that cater to the needs of both patients and healthcare providers.

Growing Demand for Home Healthcare Solutions

The shift towards home healthcare solutions is significantly impacting the Insulin Syringes Market. With an increasing number of patients opting for self-management of their diabetes, the demand for insulin syringes suitable for home use is on the rise. This trend is further supported by the growing availability of educational resources and training programs that empower patients to administer their insulin effectively. The convenience of home healthcare not only enhances patient autonomy but also reduces the strain on healthcare facilities. As a result, the Insulin Syringes Market is likely to experience a surge in demand for user-friendly and portable insulin delivery systems that cater to the needs of patients managing their diabetes at home.

Market Segment Insights

By Syringe Size: 1CC Syringe (Largest) vs. 3/10 CC Syringe (Fastest-Growing)

In the Insulin Syringes Market, the distribution among syringe sizes showcases the 1CC syringe (1ml) as the dominant player, capturing a significant portion of the market share due to its versatility and widespread use among diabetes patients. The 3/10 CC syringe (0.3ml), while smaller in market share, is rapidly gaining traction among users who prefer lower doses, reflecting a shifting preference towards precision and convenience in insulin management. The growth trends in this segment are largely driven by increasing diabetes prevalence and advancements in insulin delivery technology. Consumers are increasingly opting for specific syringe sizes that cater to their dosages, which has positioned the 3/10 CC syringe as the fastest-growing category. Innovations related to <a href="https://www.marketresearchfuture.com/reports/syringes-market-19219">syringe </a>design and patient education are further propelling this segment, thus influencing market dynamics favorably.

1/2 CC Syringe (Dominant) vs. Others (Emerging)

The 1/2 CC syringe (0.5ml) stands out as a dominant segment in the Insulin Syringes Market, known for its balanced capacity that appeals to a wide range of insulin-dependent patients. It offers an optimal solution for those requiring mid-range doses, ensuring both efficiency and comfort in administering insulin. In contrast, the 'Others' category includes a variety of less common syringe sizes, which while emerging, cater to niche markets and specific patient needs. This segment is growing in response to personalized medicine trends, as healthcare providers look for tailored solutions for diabetes management. As more patients seek syringes that accommodate their unique dosing requirements, the 'Others' segment is expected to gradually increase its market presence.

By Disease: Type 1 Diabetes (Largest) vs. Type 2 Diabetes (Fastest-Growing)

In the Insulin Syringes Market, Type 1 <a href="https://www.marketresearchfuture.com/reports/diabetes-market-2966">Diabetes </a>currently holds the largest share of the market, reflecting the significant prevalence of this condition among younger patients and the increasing awareness regarding its management. The reliance on insulin therapy for Type 1 patients has fueled a steady demand for insulin syringes, ensuring that this segment remains a key component of the market landscape.

Type 1 Diabetes (Dominant) vs. Type 2 Diabetes (Emerging)

<a href="https://www.marketresearchfuture.com/reports/type-1-diabetes-treatment-market-8199">Type 1 Diabetes</a> is characterized by the absolute dependence on insulin due to the autoimmune destruction of insulin-producing pancreatic beta cells, necessitating consistent insulin administration through syringes. This segment dominates the market driven by a higher prevalence in the pediatric population and continuous advancements in syringe technology. In contrast, Type 2 Diabetes is emerging rapidly due to lifestyle changes and increasing obesity rates. Patients often require insulin therapy as the disease progresses, which drives demand for insulin syringes. Health education and preventive measures are pivotal in managing Type 2 Diabetes, suggesting growth potential in this segment as awareness increases.

By End-use: Hospitals & Clinics (Largest) vs. Homecare Settings (Fastest-Growing)

In the Insulin Syringes Market, the end-use segment is primarily dominated by hospitals and clinics, which account for a significant portion of the overall market share. These settings benefit from high patient inflow and the need for regular insulin administration among diabetic patients, leading to sustained demand for syringes. Homecare settings are also notable, emerging rapidly due to increased patient preferences for self-monitoring and self-administration of insulin, incentivized by rising health awareness and technological advancements. The growth trends in this segment are heavily influenced by an aging population and a rise in diabetes cases globally. Additionally, the transition towards homecare settings is accelerated by convenience, patient empowerment, and technological innovations like <a href="https://www.marketresearchfuture.com/reports/smart-insulin-pens-market-6789">smart insulin pens</a>. Furthermore, hospitals continue to invest in advanced medical devices, including prefilled syringes, to enhance patient care, while homecare settings experience growth due to flexible treatment options and easier accessibility to insulin management tools.

Hospitals &amp; Clinics (Dominant) vs. Homecare Settings (Emerging)

Hospitals and clinics remain the dominant end-users in the Insulin Syringes Market owing to their robust infrastructure and consistent patient flow, providing a stable demand for insulin delivery solutions. These facilities are equipped with trained healthcare professionals who ensure proper administration techniques, enhancing patient safety and outcomes. On the other hand, homecare settings are emerging as a significant segment, driven by patients' desire for autonomy in managing their diabetes. This growth is supported by the increasing availability of user-friendly insulin syringes and educational resources promoting self-administration. As healthcare shifts towards more personalized and accessible solutions, both segments are poised for continued evolution, with hospitals focusing on advanced therapeutic technologies and homecare embracing convenience and flexibility.

Get more detailed insights about Insulin Syringes Market Research Report 2035

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for insulin syringes, holding approximately 45% of the global share. The region's growth is driven by increasing diabetes prevalence, technological advancements in syringe design, and supportive healthcare policies. Regulatory bodies like the FDA have streamlined approval processes for innovative devices, further boosting market growth. The rising demand for home healthcare solutions is also a significant catalyst for this market. The United States is the leading country in this region, with major players like Becton Dickinson and Eli Lilly dominating the market. Canada follows as the second-largest market, benefiting from a robust healthcare system and increasing awareness about diabetes management. The competitive landscape is characterized by continuous innovation and strategic partnerships among key players, ensuring a steady supply of advanced insulin delivery systems.

Europe : Emerging Market with Growth Potential

Europe is witnessing significant growth in the insulin syringes market, holding around 30% of the global share. The increasing incidence of diabetes, coupled with an aging population, is driving demand for insulin delivery devices. Regulatory frameworks in countries like Germany and France are becoming more favorable, promoting the adoption of advanced insulin syringes. The European Medicines Agency (EMA) is actively working to enhance the approval process for innovative medical devices, which is expected to further stimulate market growth. Germany and France are the leading countries in this region, with a strong presence of key players such as Sanofi and Roche. The competitive landscape is marked by a focus on product innovation and strategic collaborations among manufacturers. The market is also influenced by the rising trend of self-administration of insulin, leading to increased demand for user-friendly and efficient syringe designs. This trend is expected to continue, driving further growth in the coming years.

Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is emerging as a significant player in the insulin syringes market, accounting for approximately 20% of the global share. The region's growth is fueled by rising diabetes prevalence, increasing healthcare expenditure, and government initiatives aimed at improving diabetes management. Countries like India and China are witnessing a surge in demand for insulin delivery devices, supported by favorable regulatory environments that encourage innovation and accessibility. China and India are the leading markets in this region, with a growing number of local and international players entering the market. The competitive landscape is characterized by a mix of established companies and new entrants, focusing on affordability and accessibility of insulin syringes. The presence of key players like Terumo Corporation and Medtronic is enhancing the market dynamics, ensuring a steady supply of advanced products tailored to meet local needs.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually emerging in the insulin syringes market, holding about 5% of the global share. The growth is primarily driven by increasing diabetes cases and a rising awareness of diabetes management. Governments in several countries are implementing health initiatives to improve access to diabetes care, which is expected to boost the demand for insulin delivery devices. Regulatory bodies are also working towards establishing clearer guidelines for medical devices, facilitating market entry for new products. South Africa and the UAE are the leading countries in this region, with a growing number of healthcare facilities and increasing investments in healthcare infrastructure. The competitive landscape is still developing, with both local and international players striving to capture market share. The presence of key players like Owen Mumford is helping to enhance product availability and drive innovation in insulin delivery systems, paving the way for future growth in this untapped market.

Key Players and Competitive Insights

The Insulin Syringes Market is characterized by a dynamic competitive landscape, driven by increasing diabetes prevalence and the growing demand for efficient insulin delivery systems. Major players such as Becton Dickinson (US), Novo Nordisk (DK), and Eli Lilly (US) are strategically positioned to leverage innovation and expand their market presence. Becton Dickinson (US) focuses on enhancing product offerings through technological advancements, while Novo Nordisk (DK) emphasizes partnerships to broaden its distribution channels. Eli Lilly (US) is actively pursuing digital transformation initiatives to improve patient engagement and streamline operations. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and responsiveness to market needs.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The Insulin Syringes Market appears moderately fragmented, with key players exerting considerable influence over market dynamics. This fragmentation allows for niche players to emerge, yet the collective strength of major companies shapes pricing strategies and product availability, creating a complex interplay of competition.
In August 2025, Becton Dickinson (US) announced the launch of a new smart insulin syringe designed to provide real-time data on insulin administration. This innovation is significant as it aligns with the growing trend towards digital health solutions, potentially improving patient adherence and outcomes. The introduction of such technology not only enhances Becton Dickinson's product portfolio but also positions the company as a leader in the integration of digital tools within diabetes management.
In September 2025, Novo Nordisk (DK) entered a strategic partnership with a leading telehealth provider to enhance remote patient monitoring capabilities. This collaboration is crucial as it reflects the increasing importance of telehealth in chronic disease management, particularly for diabetes care. By integrating their insulin delivery systems with telehealth services, Novo Nordisk aims to provide a more comprehensive solution that addresses patient needs beyond just medication delivery.
In July 2025, Eli Lilly (US) expanded its manufacturing capabilities in Europe to meet the rising demand for insulin syringes. This expansion is indicative of the company's commitment to ensuring supply chain reliability and responsiveness to market fluctuations. By increasing production capacity, Eli Lilly not only strengthens its market position but also mitigates potential supply chain disruptions, which are increasingly critical in today's global market.
As of October 2025, current competitive trends in the Insulin Syringes Market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to enhance product offerings. The competitive landscape is shifting from traditional price-based competition towards a focus on innovation, technology, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely achieve a sustainable competitive advantage in the future.

Key Companies in the Insulin Syringes Market include

Industry Developments

Future Outlook

Insulin Syringes Market Future Outlook

The Insulin Syringes Market is projected to grow at a 4.2% CAGR from 2025 to 2035, driven by increasing diabetes prevalence, technological advancements, and rising healthcare expenditure.

New opportunities lie in:

  • Expansion of smart insulin delivery devices
  • Development of eco-friendly syringe materials
  • Partnerships with telehealth platforms for remote patient monitoring

By 2035, the market is expected to achieve robust growth, reflecting evolving healthcare needs and technological innovations.

Market Segmentation

Insulin Syringes Market Disease Outlook

  • Type 1 Diabetes
  • Type 2 Diabetes

Insulin Syringes Market End-use Outlook

  • Hospitals & Clinics
  • Homecare Settings
  • Others

Insulin Syringes Market Syringe Size Outlook

  • 3/10 CC Syringe (0.3ml)
  • 1/2 CC Syringe (0.5ml)
  • 1CC Syringe (1ml)
  • Others

Report Scope

MARKET SIZE 2024 1.844(USD Billion)
MARKET SIZE 2025 1.922(USD Billion)
MARKET SIZE 2035 2.901(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.2% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Becton Dickinson (US), Novo Nordisk (DK), Sanofi (FR), Eli Lilly (US), Terumo Corporation (JP), Medtronic (US), Roche (CH), Ypsomed (CH), Owen Mumford (GB)
Segments Covered Syringe Size, Disease, End-use, Region
Key Market Opportunities Integration of smart technology in Insulin Syringes Market enhances patient adherence and monitoring capabilities.
Key Market Dynamics Rising demand for insulin syringes driven by increasing diabetes prevalence and advancements in injection technology.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Insulin Syringes Market by 2035?

<p>The Insulin Syringes Market is projected to reach a valuation of 2.901 USD Billion by 2035.</p>

What was the market valuation of the Insulin Syringes Market in 2024?

<p>In 2024, the Insulin Syringes Market was valued at 1.844 USD Billion.</p>

What is the expected CAGR for the Insulin Syringes Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Insulin Syringes Market during the forecast period 2025 - 2035 is 4.2%.</p>

Which companies are considered key players in the Insulin Syringes Market?

<p>Key players in the Insulin Syringes Market include Becton Dickinson, Novo Nordisk, Sanofi, Eli Lilly, Terumo Corporation, Medtronic, Roche, Ypsomed, and Owen Mumford.</p>

What are the projected revenues for Type 1 and Type 2 Diabetes segments by 2035?

<p>By 2035, the projected revenues for Type 1 Diabetes and Type 2 Diabetes segments are expected to be 1.45 USD Billion and 1.451 USD Billion, respectively.</p>

How do the revenues of 3/10 CC Syringes compare to 1CC Syringes in 2024?

<p>In 2024, the revenue for 3/10 CC Syringes was 0.553 USD Billion, while 1CC Syringes also generated 0.553 USD Billion.</p>

What is the expected revenue for insulin syringes used in homecare settings by 2035?

The expected revenue for insulin syringes used in homecare settings by 2035 is projected to be 1.299 USD Billion.

What segment generated the highest revenue in the Insulin Syringes Market in 2024?

In 2024, the segment for Type 1 Diabetes generated the highest revenue at 0.922 USD Billion.

What is the revenue projection for the 'Others' category in the Syringe Size segment by 2035?

The revenue projection for the 'Others' category in the Syringe Size segment by 2035 is expected to be 0.677 USD Billion.

How does the revenue for hospitals and clinics compare to homecare settings in 2024?

In 2024, the revenue for hospitals and clinics was 0.738 USD Billion, while homecare settings generated a similar revenue of 0.738 USD Billion.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Syringe Size (USD Billion)
    2. | | 4.1.1 3/10 CC Syringe (0.3ml)
    3. | | 4.1.2 1/2 CC Syringe (0.5ml)
    4. | | 4.1.3 1CC Syringe (1ml)
    5. | | 4.1.4 Others
    6. | 4.2 Healthcare, BY Disease (USD Billion)
    7. | | 4.2.1 Type 1 Diabetes
    8. | | 4.2.2 Type 2 Diabetes
    9. | 4.3 Healthcare, BY End-use (USD Billion)
    10. | | 4.3.1 Hospitals & Clinics
    11. | | 4.3.2 Homecare Settings
    12. | | 4.3.3 Others
    13. | 4.4 Healthcare, BY Region (USD Billion)
    14. | | 4.4.1 North America
    15. | | | 4.4.1.1 US
    16. | | | 4.4.1.2 Canada
    17. | | 4.4.2 Europe
    18. | | | 4.4.2.1 Germany
    19. | | | 4.4.2.2 UK
    20. | | | 4.4.2.3 France
    21. | | | 4.4.2.4 Russia
    22. | | | 4.4.2.5 Italy
    23. | | | 4.4.2.6 Spain
    24. | | | 4.4.2.7 Rest of Europe
    25. | | 4.4.3 APAC
    26. | | | 4.4.3.1 China
    27. | | | 4.4.3.2 India
    28. | | | 4.4.3.3 Japan
    29. | | | 4.4.3.4 South Korea
    30. | | | 4.4.3.5 Malaysia
    31. | | | 4.4.3.6 Thailand
    32. | | | 4.4.3.7 Indonesia
    33. | | | 4.4.3.8 Rest of APAC
    34. | | 4.4.4 South America
    35. | | | 4.4.4.1 Brazil
    36. | | | 4.4.4.2 Mexico
    37. | | | 4.4.4.3 Argentina
    38. | | | 4.4.4.4 Rest of South America
    39. | | 4.4.5 MEA
    40. | | | 4.4.5.1 GCC Countries
    41. | | | 4.4.5.2 South Africa
    42. | | | 4.4.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Becton Dickinson (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Novo Nordisk (DK)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Sanofi (FR)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Eli Lilly (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Terumo Corporation (JP)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Medtronic (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Roche (CH)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Ypsomed (CH)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Owen Mumford (GB)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY SYRINGE SIZE
    4. | 6.4 US MARKET ANALYSIS BY DISEASE
    5. | 6.5 US MARKET ANALYSIS BY END-USE
    6. | 6.6 CANADA MARKET ANALYSIS BY SYRINGE SIZE
    7. | 6.7 CANADA MARKET ANALYSIS BY DISEASE
    8. | 6.8 CANADA MARKET ANALYSIS BY END-USE
    9. | 6.9 EUROPE MARKET ANALYSIS
    10. | 6.10 GERMANY MARKET ANALYSIS BY SYRINGE SIZE
    11. | 6.11 GERMANY MARKET ANALYSIS BY DISEASE
    12. | 6.12 GERMANY MARKET ANALYSIS BY END-USE
    13. | 6.13 UK MARKET ANALYSIS BY SYRINGE SIZE
    14. | 6.14 UK MARKET ANALYSIS BY DISEASE
    15. | 6.15 UK MARKET ANALYSIS BY END-USE
    16. | 6.16 FRANCE MARKET ANALYSIS BY SYRINGE SIZE
    17. | 6.17 FRANCE MARKET ANALYSIS BY DISEASE
    18. | 6.18 FRANCE MARKET ANALYSIS BY END-USE
    19. | 6.19 RUSSIA MARKET ANALYSIS BY SYRINGE SIZE
    20. | 6.20 RUSSIA MARKET ANALYSIS BY DISEASE
    21. | 6.21 RUSSIA MARKET ANALYSIS BY END-USE
    22. | 6.22 ITALY MARKET ANALYSIS BY SYRINGE SIZE
    23. | 6.23 ITALY MARKET ANALYSIS BY DISEASE
    24. | 6.24 ITALY MARKET ANALYSIS BY END-USE
    25. | 6.25 SPAIN MARKET ANALYSIS BY SYRINGE SIZE
    26. | 6.26 SPAIN MARKET ANALYSIS BY DISEASE
    27. | 6.27 SPAIN MARKET ANALYSIS BY END-USE
    28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY SYRINGE SIZE
    29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY DISEASE
    30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY END-USE
    31. | 6.31 APAC MARKET ANALYSIS
    32. | 6.32 CHINA MARKET ANALYSIS BY SYRINGE SIZE
    33. | 6.33 CHINA MARKET ANALYSIS BY DISEASE
    34. | 6.34 CHINA MARKET ANALYSIS BY END-USE
    35. | 6.35 INDIA MARKET ANALYSIS BY SYRINGE SIZE
    36. | 6.36 INDIA MARKET ANALYSIS BY DISEASE
    37. | 6.37 INDIA MARKET ANALYSIS BY END-USE
    38. | 6.38 JAPAN MARKET ANALYSIS BY SYRINGE SIZE
    39. | 6.39 JAPAN MARKET ANALYSIS BY DISEASE
    40. | 6.40 JAPAN MARKET ANALYSIS BY END-USE
    41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY SYRINGE SIZE
    42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY DISEASE
    43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY END-USE
    44. | 6.44 MALAYSIA MARKET ANALYSIS BY SYRINGE SIZE
    45. | 6.45 MALAYSIA MARKET ANALYSIS BY DISEASE
    46. | 6.46 MALAYSIA MARKET ANALYSIS BY END-USE
    47. | 6.47 THAILAND MARKET ANALYSIS BY SYRINGE SIZE
    48. | 6.48 THAILAND MARKET ANALYSIS BY DISEASE
    49. | 6.49 THAILAND MARKET ANALYSIS BY END-USE
    50. | 6.50 INDONESIA MARKET ANALYSIS BY SYRINGE SIZE
    51. | 6.51 INDONESIA MARKET ANALYSIS BY DISEASE
    52. | 6.52 INDONESIA MARKET ANALYSIS BY END-USE
    53. | 6.53 REST OF APAC MARKET ANALYSIS BY SYRINGE SIZE
    54. | 6.54 REST OF APAC MARKET ANALYSIS BY DISEASE
    55. | 6.55 REST OF APAC MARKET ANALYSIS BY END-USE
    56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. | 6.57 BRAZIL MARKET ANALYSIS BY SYRINGE SIZE
    58. | 6.58 BRAZIL MARKET ANALYSIS BY DISEASE
    59. | 6.59 BRAZIL MARKET ANALYSIS BY END-USE
    60. | 6.60 MEXICO MARKET ANALYSIS BY SYRINGE SIZE
    61. | 6.61 MEXICO MARKET ANALYSIS BY DISEASE
    62. | 6.62 MEXICO MARKET ANALYSIS BY END-USE
    63. | 6.63 ARGENTINA MARKET ANALYSIS BY SYRINGE SIZE
    64. | 6.64 ARGENTINA MARKET ANALYSIS BY DISEASE
    65. | 6.65 ARGENTINA MARKET ANALYSIS BY END-USE
    66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY SYRINGE SIZE
    67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE
    68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USE
    69. | 6.69 MEA MARKET ANALYSIS
    70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY SYRINGE SIZE
    71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY DISEASE
    72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY END-USE
    73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY SYRINGE SIZE
    74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY DISEASE
    75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY END-USE
    76. | 6.76 REST OF MEA MARKET ANALYSIS BY SYRINGE SIZE
    77. | 6.77 REST OF MEA MARKET ANALYSIS BY DISEASE
    78. | 6.78 REST OF MEA MARKET ANALYSIS BY END-USE
    79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. | 6.80 RESEARCH PROCESS OF MRFR
    81. | 6.81 DRO ANALYSIS OF HEALTHCARE
    82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. | 6.85 HEALTHCARE, BY SYRINGE SIZE, 2024 (% SHARE)
    86. | 6.86 HEALTHCARE, BY SYRINGE SIZE, 2024 TO 2035 (USD Billion)
    87. | 6.87 HEALTHCARE, BY DISEASE, 2024 (% SHARE)
    88. | 6.88 HEALTHCARE, BY DISEASE, 2024 TO 2035 (USD Billion)
    89. | 6.89 HEALTHCARE, BY END-USE, 2024 (% SHARE)
    90. | 6.90 HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Billion)
    91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY DISEASE, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY END-USE, 2025-2035 (USD Billion)
    7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    8. | | 7.3.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    9. | | 7.3.2 BY DISEASE, 2025-2035 (USD Billion)
    10. | | 7.3.3 BY END-USE, 2025-2035 (USD Billion)
    11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    12. | | 7.4.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    13. | | 7.4.2 BY DISEASE, 2025-2035 (USD Billion)
    14. | | 7.4.3 BY END-USE, 2025-2035 (USD Billion)
    15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.5.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    17. | | 7.5.2 BY DISEASE, 2025-2035 (USD Billion)
    18. | | 7.5.3 BY END-USE, 2025-2035 (USD Billion)
    19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    20. | | 7.6.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    21. | | 7.6.2 BY DISEASE, 2025-2035 (USD Billion)
    22. | | 7.6.3 BY END-USE, 2025-2035 (USD Billion)
    23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.7.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    25. | | 7.7.2 BY DISEASE, 2025-2035 (USD Billion)
    26. | | 7.7.3 BY END-USE, 2025-2035 (USD Billion)
    27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.8.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    29. | | 7.8.2 BY DISEASE, 2025-2035 (USD Billion)
    30. | | 7.8.3 BY END-USE, 2025-2035 (USD Billion)
    31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    32. | | 7.9.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    33. | | 7.9.2 BY DISEASE, 2025-2035 (USD Billion)
    34. | | 7.9.3 BY END-USE, 2025-2035 (USD Billion)
    35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    36. | | 7.10.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    37. | | 7.10.2 BY DISEASE, 2025-2035 (USD Billion)
    38. | | 7.10.3 BY END-USE, 2025-2035 (USD Billion)
    39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.11.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    41. | | 7.11.2 BY DISEASE, 2025-2035 (USD Billion)
    42. | | 7.11.3 BY END-USE, 2025-2035 (USD Billion)
    43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.12.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    45. | | 7.12.2 BY DISEASE, 2025-2035 (USD Billion)
    46. | | 7.12.3 BY END-USE, 2025-2035 (USD Billion)
    47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    48. | | 7.13.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    49. | | 7.13.2 BY DISEASE, 2025-2035 (USD Billion)
    50. | | 7.13.3 BY END-USE, 2025-2035 (USD Billion)
    51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.14.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    53. | | 7.14.2 BY DISEASE, 2025-2035 (USD Billion)
    54. | | 7.14.3 BY END-USE, 2025-2035 (USD Billion)
    55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    56. | | 7.15.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    57. | | 7.15.2 BY DISEASE, 2025-2035 (USD Billion)
    58. | | 7.15.3 BY END-USE, 2025-2035 (USD Billion)
    59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    60. | | 7.16.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    61. | | 7.16.2 BY DISEASE, 2025-2035 (USD Billion)
    62. | | 7.16.3 BY END-USE, 2025-2035 (USD Billion)
    63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.17.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    65. | | 7.17.2 BY DISEASE, 2025-2035 (USD Billion)
    66. | | 7.17.3 BY END-USE, 2025-2035 (USD Billion)
    67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    68. | | 7.18.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    69. | | 7.18.2 BY DISEASE, 2025-2035 (USD Billion)
    70. | | 7.18.3 BY END-USE, 2025-2035 (USD Billion)
    71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    72. | | 7.19.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    73. | | 7.19.2 BY DISEASE, 2025-2035 (USD Billion)
    74. | | 7.19.3 BY END-USE, 2025-2035 (USD Billion)
    75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.20.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    77. | | 7.20.2 BY DISEASE, 2025-2035 (USD Billion)
    78. | | 7.20.3 BY END-USE, 2025-2035 (USD Billion)
    79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    80. | | 7.21.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    81. | | 7.21.2 BY DISEASE, 2025-2035 (USD Billion)
    82. | | 7.21.3 BY END-USE, 2025-2035 (USD Billion)
    83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.22.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    85. | | 7.22.2 BY DISEASE, 2025-2035 (USD Billion)
    86. | | 7.22.3 BY END-USE, 2025-2035 (USD Billion)
    87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.23.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    89. | | 7.23.2 BY DISEASE, 2025-2035 (USD Billion)
    90. | | 7.23.3 BY END-USE, 2025-2035 (USD Billion)
    91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    92. | | 7.24.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    93. | | 7.24.2 BY DISEASE, 2025-2035 (USD Billion)
    94. | | 7.24.3 BY END-USE, 2025-2035 (USD Billion)
    95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    96. | | 7.25.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    97. | | 7.25.2 BY DISEASE, 2025-2035 (USD Billion)
    98. | | 7.25.3 BY END-USE, 2025-2035 (USD Billion)
    99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.26.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    101. | | 7.26.2 BY DISEASE, 2025-2035 (USD Billion)
    102. | | 7.26.3 BY END-USE, 2025-2035 (USD Billion)
    103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.27.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    105. | | 7.27.2 BY DISEASE, 2025-2035 (USD Billion)
    106. | | 7.27.3 BY END-USE, 2025-2035 (USD Billion)
    107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    108. | | 7.28.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    109. | | 7.28.2 BY DISEASE, 2025-2035 (USD Billion)
    110. | | 7.28.3 BY END-USE, 2025-2035 (USD Billion)
    111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.29.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    113. | | 7.29.2 BY DISEASE, 2025-2035 (USD Billion)
    114. | | 7.29.3 BY END-USE, 2025-2035 (USD Billion)
    115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    116. | | 7.30.1 BY SYRINGE SIZE, 2025-2035 (USD Billion)
    117. | | 7.30.2 BY DISEASE, 2025-2035 (USD Billion)
    118. | | 7.30.3 BY END-USE, 2025-2035 (USD Billion)
    119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    120. | | 7.31.1
    121. | 7.32 ACQUISITION/PARTNERSHIP
    122. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Syringe Size (USD Billion, 2025-2035)

  • 3/10 CC Syringe (0.3ml)
  • 1/2 CC Syringe (0.5ml)
  • 1CC Syringe (1ml)
  • Others

Healthcare By Disease (USD Billion, 2025-2035)

  • Type 1 Diabetes
  • Type 2 Diabetes

Healthcare By End-use (USD Billion, 2025-2035)

  • Hospitals & Clinics
  • Homecare Settings
  • Others
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓